Loading clinical trials...

COMPLETEDNA

Graded Exposure in Patients With Painful Diabetic Neuropathy

NCT03066570•Maastricht University Medical Center

Summary

Objective: To investigate the effects of a cognitive behavioural intervention targeting specific fears in patients with painful diabetic neuropathy, on physical activity and quality of life.

Detailed Description

Intervention: Graded Exposure in vivo (GEXP) is a second-generation cognitive-behavioural intervention, and is characterized by systematic and repeated exposure to feared movements, activities and/or sensations in order to decrease fear and subsequently increase physical activity. Main study parameters/endpoints: The purpose of this project is to develop and test a cognitive behavioural intervention targeting specific fears in patients with PDN, in order to increase physical activity and improve QOL.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with type II diabetes mellitus,
•aged \> 18 years who suffer from peripheral polyneuropathy.

Exclusion Criteria

•Patients with lower limb morbidities other than PDN such as peripheral arterial disease
•severe osteoarthritis, any other neurological disease than PDN or any other disease that may cause pain in the feet and/or damage to the peripheral nervous system (e.g. ulcers).

Locations (1)

Maastricht University Medical Center

Maastricht, Limburg, Netherlands

Key Dates

Start Date

June 1, 2017

Primary Completion Date

March 18, 2019

Completion Date

March 18, 2019

Last Updated

December 3, 2020

Enrollment

ACTUAL participants

Conditions

Painful Diabetic NeuropathyDiabetic Neuropathies, PainfulNeuralgia, Diabetic

Interventions

Graded Exposure

BEHAVIORAL

Beneficial Effects of Supplementation With CRONILIEF™ (Palmitoylethanolamide Phospholipids) in Diabetic Subjects With Neuropathic Pain.

NCT07377409

Neuropathic Pain ManagementDiabetic Neuropathies, Painful+1 more

View study

COMPLETEDNA

Feasibility of Self-treatment of Painful Diabetic Neuropathy Using Electrical Vasomotor Nerve Stimulation

NCT06524284

Painful Diabetic Neuropathy

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 3, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Graded Exposure in Patients With Painful Diabetic Neuropathy

Inclusion Criteria

Exclusion Criteria

Beneficial Effects of Supplementation With CRONILIEF™ (Palmitoylethanolamide Phospholipids) in Diabetic Subjects With Neuropathic Pain.

Feasibility of Self-treatment of Painful Diabetic Neuropathy Using Electrical Vasomotor Nerve Stimulation

Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN

Axon Therapy and Conventional Medical Management for Painful Diabetic Neuropathy Compared to Sham and Conventional Medical Management

Diabetic Small Fiber Neuropathy: Clinical, Electrophysiological and Neurosonographic Study

A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy